All In Biotech

Free tool

FAERS Monitor: Takhzyro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761090 or its brand name (Takhzyro, Lanadelumab-Flyo). Reports on generic versions are filed under their own applications.

Reports

3,228

Serious

1,536

48% of reports

Hospitalization

870

Death reported

41

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema1,217
  • drug ineffective298
  • product dose omission issue265
  • weight increased245
  • weight decreased238
  • headache188
  • condition aggravated187
  • inappropriate schedule of product administration169
  • product use issue161
  • intentional product use issue157
  • injection site pain143
  • stress143
  • malaise128
  • pharyngeal swelling123
  • off label use122

Reports by year received

View as table
YearReports
20154
20162
20175
2018106
2019393
2020318
2021291
2022325
2023374
2024474
2025563
2026373

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,931 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal1,217833.2793.6896,716
pharyngeal swellingSignal12382.969.79,756
stressSignal14312.911.01,567
intentional product use issueSignal15711.710.01,529
weight increasedSignal2457.16.31,299
inappropriate schedule of product administrationSignal1696.15.3723
product dose omission issueSignal2655.95.21,082
product use issueSignal1615.64.8606
weight decreasedSignal2385.64.9896
condition aggravatedSignal1874.03.5425
injection site painSignal1433.02.6196
headache1882.01.789
malaise1281.91.655
drug ineffective2981.51.348
off label use1220.90.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.